Clinical significance of high monocyte counts for the continuous treatment with nintedanib
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Clinical significance of high monocyte counts for the continuous treatment with nintedanib ; volume:23 ; number:1 ; day:3 ; month:7 ; year:2023 ; pages:1-9 ; date:12.2023
BMC pulmonary medicine ; 23, Heft 1 (3.7.2023), 1-9, 12.2023
- Urheber
-
Tsuneyoshi, Shingo
Zaizen, Yoshiaki
Tominaga, Masaki
Matama, Goushi
Umemoto, Shushi
Ohno, Shuuhei
Takaki, Reiko
Yano, Ryo
Murotani, Kenta
Okamoto, Masaki
Hoshino, Tomoaki
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12890-023-02536-y
- URN
-
urn:nbn:de:101:1-2023110209154007845149
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:57 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Tsuneyoshi, Shingo
- Zaizen, Yoshiaki
- Tominaga, Masaki
- Matama, Goushi
- Umemoto, Shushi
- Ohno, Shuuhei
- Takaki, Reiko
- Yano, Ryo
- Murotani, Kenta
- Okamoto, Masaki
- Hoshino, Tomoaki
- SpringerLink (Online service)
Ähnliche Objekte (12)
Correction to: clinical significance of high monocyte counts for the continuous treatment with nintedanib
Prognostic significance of peripheral monocyte count in patients with extranodal natural killer/T-cell lymphoma
Low lymphocyte count and high monocyte count predicts poor prognosis of gastric cancer
Monocyte count and soluble markers of monocyte activation in people living with HIV and uninfected controls
Nintedanib-Induced Renal Thrombotic Microangiopathy
Correlation of monocyte counts with clinical outcomes in idiopathic nonspecific interstitial pneumonia
Nintedanib (Ofev) : IPF-Therapie: Frühstart erwünscht
Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib
Nintedanib: Nutzenbewertung gemäß § 35a SGB V
Nintedanib zur Therapie der radiogenen Pneumonitis
Nintedanib nutzt auch bei erhaltenem Lungenvolumen
Nintedanib downregulates the profibrotic M2 phenotype in cultured monocyte-derived macrophages obtained from systemic sclerosis patients affected by interstitial lung disease
Correction to: clinical significance of high monocyte counts for the continuous treatment with nintedanib
Prognostic significance of peripheral monocyte count in patients with extranodal natural killer/T-cell lymphoma
Low lymphocyte count and high monocyte count predicts poor prognosis of gastric cancer
Monocyte count and soluble markers of monocyte activation in people living with HIV and uninfected controls
Nintedanib-Induced Renal Thrombotic Microangiopathy
Correlation of monocyte counts with clinical outcomes in idiopathic nonspecific interstitial pneumonia
Nintedanib (Ofev) : IPF-Therapie: Frühstart erwünscht
Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib
Nintedanib: Nutzenbewertung gemäß § 35a SGB V
Nintedanib zur Therapie der radiogenen Pneumonitis
Nintedanib nutzt auch bei erhaltenem Lungenvolumen
Nintedanib downregulates the profibrotic M2 phenotype in cultured monocyte-derived macrophages obtained from systemic sclerosis patients affected by interstitial lung disease
Correction to: clinical significance of high monocyte counts for the continuous treatment with nintedanib
Prognostic significance of peripheral monocyte count in patients with extranodal natural killer/T-cell lymphoma
Low lymphocyte count and high monocyte count predicts poor prognosis of gastric cancer
Monocyte count and soluble markers of monocyte activation in people living with HIV and uninfected controls
Nintedanib-Induced Renal Thrombotic Microangiopathy
Correlation of monocyte counts with clinical outcomes in idiopathic nonspecific interstitial pneumonia
Nintedanib (Ofev) : IPF-Therapie: Frühstart erwünscht
Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib
Nintedanib: Nutzenbewertung gemäß § 35a SGB V
Nintedanib zur Therapie der radiogenen Pneumonitis
Nintedanib nutzt auch bei erhaltenem Lungenvolumen